NEW YORK (TheStreet) --Shares of Baxalta (BXLT) are up 4.47% to $39.76 in afternoon trading on Tuesday as the company moves closer to accepting a bid from rival drug maker Shire Plc (SHPG), according to Reuters.

Baxalta's board rejected an all-stock $30 billion offer from the company in August, saying that it "significantly undervalued" the company, but Shire upped the percentage of cash in the offer.

Shire offered 40% of the deal in cash this week, according to the Sunday Times, to go along with its offer of $45 per share for the U.S.-based Baxalta.

Separately, the company announced that their biosimilar candidate M923 met the primary endpoint in a pharmacokinetic trial that was initiated in February of this year.

M923 was shown to be biosimilar to AbbVie's (ABBV) highly successful Humira drug. Humira is a chemotherapy and immunosupressant that can also treat arthritis, plaque psoriasis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis.

The companies collaborated on development of the drug.

Image placeholder title

BXLT

data by

YCharts